Microbot Medical (NASDAQ: MBOT) Achieves 100% Success in Pre-Clinical Trials with LIBERTY® Surgical Robotic System
Microbot Medical’s Pre-Clinical Trials Showcase Exceptional Success Rate
Microbot Medical, the innovator behind the groundbreaking LIBERTY® Surgical Robotic System, has announced triumphant results from a comprehensive pre-clinical animal study conducted at a renowned European research facility. A team of six distinguished European interventional radiologists employed the LIBERTY® Surgical Robotic System, the first-of-its-kind single-use endovascular robotic system by Microbot Medical, performing 48 catheterizations with a remarkable 100% success rate.
Microbot Medical’s LIBERTY® Surgical Robotic System Wins User Praise
The radiologists conducted the catheterizations targeting pre-determined vascular points, including distal branches of various arteries. Real-time feedback from the users underscored the system’s user-friendliness and intuitive nature, commending its remote controller for offering seamless control over procedures.
MBOT’s Pathway to Future Clinical Trials and Commercialization
“These successful pre-clinical trials further validate the safety and effectiveness of Microbot Medical’s LIBERTY® Surgical Robotic System. We are continually fine-tuning the system in preparation for human clinical phase slated for the latter half of this year,” explained Dr. Eyal Morag, Chief Medical Officer of Microbot Medical. He added, “We believe that this success, combined with forthcoming opportunities for peer-reviewed publications, will highlight the considerable benefits that Microbot Medical’s LIBERTY® Surgical Robotic System is expected to deliver upon commercialization, thereby promoting early adoption.”
Microbot Medical is planning additional pre-clinical studies in the U.S. and other target markets, as well as the first-in-human case in markets outside the U.S., steadily progressing towards commercializing their LIBERTY® Surgical Robotic System.
Microbot Medical’s Success: Surpassing the 100th Catheterization Milestone
The 48 successful catheterizations are part of Microbot Medical’s recent accomplishment of surpassing 100 catheterizations during various pre-clinical studies, showcasing an impressive 95% success rate of reaching pre-determined vascular targets.
MBOT Market Response:
Shares of Microbot Medical are skyrocketing 156% through afternoon trading on Monday, May 22, 2023. Over the past three months, the surgical robotics company has seen average daily volume of 51,810 shares. However, volume of 129 million shares or dollar volume of around $397.32 million, has already exchanged hands through late trading. As of this writing, shares of Microbot are up 2.33% year-to-date.
Disclosure: No position. Spotlight Growth has no relationships with any of the companies mentioned in this article and did not receive payment in any form for its creation. This is an opinion article and is not meant to be financial advise. We are not broker-dealers or investment professionals. Please conduct your own due diligence. For more information on our disclosures, please visit: https://spotlightgrowth.com/disclosures/